GNOM

Global X Genomics & Biotechnology ETF (GNOM) | Rumor.io

Global X Genomics & Biotechnology ETF

GNOM

Attention (50-day avg)0%

Attention rank (50-day avg)#1,193

Bullish sentiment (50-day avg)33%

Price to earnings ratio0

Net assets0

Expense ratio0.01%

Social

What share of all ETF conversation is about GNOM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0% +0	0% +0	0% +0

Jun 30

GNOM is considered a better long-term bet on genomic advances than ARKG due to its lower expense ratio and potential for lower volatility.
GNOM replicates the Solactive Genomics Index, which uses a natural language processing algorithm to select holdings based on publicly available information.
The overlap between GNOM and ARKG is 12 out of 40 and 60 holdings respectively, indicating some similarities but not a significant duplication of holdings.

Generated by AI

Sentiment

Of the messages about GNOM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	42.86% +17.86	97.11% +51.36
Bearish	—	—	57.14% -17.86	2.89% -51.36

Bullish· Jul 18

The Global X Genomics & Biotechnology ETF ($GNOM) has shown significant gains, with one user reporting a 19% profit from 2.54 to 3.10.
$GNOM has been identified as a potential long-term investment opportunity, with one user expressing interest in going long at the low of day (LOD).
The ETF is expected to continue its upward trend, with one user predicting another run to $3 or higher, potentially with multiple entry points around 2.80 or lower.

Bearish· Jul 12

$GNOM may break down below $2.50, with one trader looking to get back in below this price.
$GNOM's recent price action is consistent with a pump and dump scheme, with one trader suggesting it will break down like $ARNA did.
$GNOM's high trading volume may not be sustainable, with one trader noting that 5.2 million shares traded in a short period, which could lead to a drop.

Generated by AI

Topics

Of the messages about GNOM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	—	—	100%	57.23%
Macro	—	—	0%	42.77%

Sep 17

GNOM has announced a definitive agreement to merge with BGI-Shenzhen at $3.15 cash, which is expected to be a buyout.
Technical analysts are discussing the implications of the potential buyout, including the possibility of a higher bid and the potential for a "Baird Raid" call.
The buyout has led to significant price movement, with GNOM selling at $3.07 from $2.67, and some investors taking profits while others are looking to load more shares.

Generated by AI

Community

Of the messages about GNOM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	36.36%	17.39%	37.84%	7.29%
Newcomers	63.64%	82.61%	62.16%	92.71%

Jun 30

Newcomers to GNOM are comparing it to ARKG, focusing on the lower expense ratio and potential for lower volatility in GNOM.
Some newcomers are looking into the holdings of GNOM, noting that it seems to be a more representative ETF of the genomics field compared to ARKG.
Others are questioning how GNOM selects its holdings, particularly how it adds companies that are being heavily discussed online, even if they are not necessarily well-represented in the genomics field.

Generated by AI

Two genomics ETFs share the same buzzwords on every screener, but their structures have sent them on wildly different paths through rate shocks, biotech meltdowns, and the current rally. The one that looks riskier on paper may actually be the smarter satellite bet right now.

2mo agoYahoo Finance

Also Discussed

Investors talking about GNOM also mention

#	Name	Attention
1	ARK Genomic Revolution ETFARKG	0.25%+0.09
2	iShares Genomics Immunology and Healthcare ETFIDNA	0.01%new
3	Invesco Biotechnology & Genome ETFPBE	0%0
4	iShares Biotechnology ETFIBB	0.01%0
5	HZNP - Horizon Therapeutics Public Limited Company	——
6	GXTG - Global X Thematic Growth ETF	——
7	Global X E-Commerce ETFEBIZ	0%0
8	Vanguard Health Care ETFVHT	0.13%+0.12
9	SPDR S&P Biotech ETFXBI	0.42%+0.08
10	Ani Pharmaceuticals, Inc.ANIP	0%new

Global X Genomics & Biotechnology ETF

Global X Genomics & Biotechnology ETF is an exchange-traded fund that provides focused exposure to companies involved in genomic science and biotechnology. The fund tracks the Solactive Genomics Index and invests primarily in businesses engaged in gene editing, genomic sequencing, genetic medicine and therapy, computational genomics, and related life sciences applications. Its portfolio is concentrated in healthcare and biotechnology firms, including developers of diagnostics, research tools, and advanced therapeutics that support innovation across precision medicine and biological research. By targeting this specialized segment of the market, Global X Genomics & Biotechnology ETF offers investors a single fund that reflects the growth and commercialization of genomics-driven technologies and services across global healthcare and biotech industries.

Location

United States

Social

What share of all ETF conversation is about GNOM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0% +0	0% +0	0% +0

Jun 30

GNOM is considered a better long-term bet on genomic advances than ARKG due to its lower expense ratio and potential for lower volatility.
GNOM replicates the Solactive Genomics Index, which uses a natural language processing algorithm to select holdings based on publicly available information.
The overlap between GNOM and ARKG is 12 out of 40 and 60 holdings respectively, indicating some similarities but not a significant duplication of holdings.

Generated by AI

Sentiment

Of the messages about GNOM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	42.86% +17.86	97.11% +51.36
Bearish	—	—	57.14% -17.86	2.89% -51.36

Bullish· Jul 18

The Global X Genomics & Biotechnology ETF ($GNOM) has shown significant gains, with one user reporting a 19% profit from 2.54 to 3.10.
$GNOM has been identified as a potential long-term investment opportunity, with one user expressing interest in going long at the low of day (LOD).
The ETF is expected to continue its upward trend, with one user predicting another run to $3 or higher, potentially with multiple entry points around 2.80 or lower.

Bearish· Jul 12

$GNOM may break down below $2.50, with one trader looking to get back in below this price.
$GNOM's recent price action is consistent with a pump and dump scheme, with one trader suggesting it will break down like $ARNA did.
$GNOM's high trading volume may not be sustainable, with one trader noting that 5.2 million shares traded in a short period, which could lead to a drop.

Generated by AI

Topics

Of the messages about GNOM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	—	—	100%	57.23%
Macro	—	—	0%	42.77%

Sep 17

GNOM has announced a definitive agreement to merge with BGI-Shenzhen at $3.15 cash, which is expected to be a buyout.
Technical analysts are discussing the implications of the potential buyout, including the possibility of a higher bid and the potential for a "Baird Raid" call.
The buyout has led to significant price movement, with GNOM selling at $3.07 from $2.67, and some investors taking profits while others are looking to load more shares.

Generated by AI

Community

Of the messages about GNOM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	36.36%	17.39%	37.84%	7.29%
Newcomers	63.64%	82.61%	62.16%	92.71%

Jun 30

Newcomers to GNOM are comparing it to ARKG, focusing on the lower expense ratio and potential for lower volatility in GNOM.
Some newcomers are looking into the holdings of GNOM, noting that it seems to be a more representative ETF of the genomics field compared to ARKG.
Others are questioning how GNOM selects its holdings, particularly how it adds companies that are being heavily discussed online, even if they are not necessarily well-represented in the genomics field.

Generated by AI

Global X Genomics & Biotechnology ETF

Social

Jun 30

Sentiment

Bullish· Jul 18

Bearish· Jul 12

Topics

Sep 17

Community

Jun 30

News

ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?

Also Discussed

Global X Genomics & Biotechnology ETF

Company Information

Location

News

ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?

Also Discussed

Social

Jun 30

Sentiment

Bullish· Jul 18

Bearish· Jul 12

Topics

Sep 17

Community

Jun 30